|
gptkbp:instanceOf
|
gptkb:drug
norepinephrine reuptake inhibitor
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06BA09
|
|
gptkbp:brand
|
gptkb:Strattera
|
|
gptkbp:CASNumber
|
gptkb:83015-26-3
|
|
gptkbp:chemicalFormula
|
phenoxypropylamine derivative
|
|
gptkbp:color
|
white (powder)
|
|
gptkbp:compatibleWith
|
stimulant
|
|
gptkbp:contraindication
|
severe cardiovascular disorders
narrow angle glaucoma
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:eliminationHalfLife
|
5.2 hours
19 hours (CYP2D6 poor metabolizers)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstMarketedIn
|
gptkb:United_States
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
gptkb:C17H21NO
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
atomoxetine
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
CYP2D6 inhibitors
|
|
gptkbp:KEGGID
|
D07441
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective norepinephrine reuptake inhibition
|
|
gptkbp:MedlinePlusID
|
a603013
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
liver
|
|
gptkbp:notControlledSubstance
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1176
gptkb:DB00289
54841
|
|
gptkbp:riskFactor
|
liver injury
suicidal ideation (in children and adolescents)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
increased heart rate
insomnia
dry mouth
decreased appetite
increased blood pressure
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
ASW034S0B8
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
|
|
gptkbp:bfsParent
|
gptkb:Attention_Deficit_Hyperactivity_Disorder
|
|
gptkbp:bfsLayer
|
6
|